
Opinion|Videos|June 5, 2024
Evolving Commercialization and Distribution Models for PDTs
The panel discusses the challenges of delivering prescription digital therapeutics (PDTs) to patients, challenges caused by PDTs being considered behavioral health benefits, pharmacy benefits, medical benefits, and durable medical equipment benefits.
Advertisement
Episodes in this series

Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
In Vivo CAR T Takes Center Stage, With Results Shared for 4 MRD-Negative Patients
2
Price Transparency With Gaps: Assessing the Completeness of Payer Transparency in Coverage Data
3
Adolescents Saw Mental Health Gains After School Reopened Post Pandemic
4
Camizestrant-Related Photopsia Mostly Mild, Nondisabling in Patients With Advanced Breast Cancer: Adam Brufsky, MD, PhD
5













































